Lexaria Bioscience (LEXX) Other Non Operating Income (2022 - 2026)
Lexaria Bioscience (LEXX) posted Other Non Operating Income of $837.0 for Q2 2026, down 52.66% sequentially from $1768.0 in Q1 2026, and up 102.08% YoY from $414.19 in Q2 2025.
Lexaria Bioscience (LEXX) Other Non Operating Income (2022 - 2026) Analysis & Trends
Lexaria Bioscience has reported Other Non Operating Income for 5 years, with the latest figure at $837.0 in Q2 2026.
- Quarterly Other Non Operating Income rose 102.08% year-over-year to $837.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was -$28106.0 (down 404.32% YoY) and the FY2025 annual result came in at -$30697.0, up 44.71% from the prior year.
- Other Non Operating Income declined to $837.0 in Q2 2026 per LEXX's latest filing, from $1768.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $34040.0 in Q1 2025 and troughed at -$134902.0 in Q3 2023.
- A 5-year average of -$18946.6 and a median of -$8631.0 in 2025 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income plunged 339.28% in 2024, then soared 122.89% in 2025.
- Over 5 years, Other Non Operating Income stood at -$73887.0 in 2022, then surged by 37.88% to -$45896.0 in 2023, then surged by 65.31% to -$15921.0 in 2024, then sank by 38.68% to -$22080.0 in 2025, then surged by 103.79% to $837.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $837.0, $1768.0, and -$22080.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 837.00 |
| Feb 28, 2026 | 1,768.00 |
| Nov 30, 2025 | -22,080.00 |
| Aug 31, 2025 | -8,631.00 |
| May 31, 2025 | -40,185.00 |
| Feb 28, 2025 | 34,040.00 |
| Nov 30, 2024 | -15,921.00 |
| Aug 31, 2024 | 16,493.00 |
| May 31, 2024 | -41,393.00 |
| Feb 29, 2024 | 15,272.00 |
| Nov 30, 2023 | -45,896.00 |
| Aug 31, 2023 | -134,902.00 |
| May 31, 2023 | 17,299.00 |
| Feb 28, 2023 | 12,987.00 |
| Nov 30, 2022 | -73,887.00 |